Haisco Pharmaceutical Group has filed a patent for a compound of formula (I) and its various forms, including stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, co-crystals, and prodrugs. The compound is claimed to be a PB2 inhibitor for the treatment of related diseases. GlobalData’s report on Haisco Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Haisco Pharmaceutical Group, Peptide nano-particle conjugates was a key innovation area identified from patents. Haisco Pharmaceutical Group's grant share as of September 2023 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230265107A1) describes a compound of formula (I) and its various derivatives, including stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, co-crystals, and prodrugs. The compound has potential applications in the treatment of PB2-mediated diseases, such as tumors and autoimmune diseases.
The compound of formula (I) is represented as Cy1-L1-Cy2-L2-Cy3, where Cy1, Cy2, and Cy3 are selected from specific groups. The patent claims also provide additional structures (II, III, IV, and V) for the compound, which involve different arrangements of the Cy1, Cy2, and Cy3 groups.
The patent claims further specify the possible substitutions and variations for the Cy1, Cy2, and Cy3 groups. For example, Cy1 can be selected from specific groups, and each Rcy3 (substituents on Cy3) can be independently chosen from F, Cl, and CN. Similarly, Cy2a and Cy2b have specific selections, and Cy2c can be a 5-membered heteroaryl, 6-membered heteroaryl, or C3-6 cycloalkyl, optionally substituted with specific groups.
The patent claims also describe the possible substitutions for the RA group, which can be independently selected from various groups, optionally further substituted with additional groups. Additionally, RB and RC can be independently selected from specific groups.
The patent claims not only cover the compound itself but also extend to pharmaceutical compositions containing the compound and a pharmaceutically acceptable carrier and/or excipient. Furthermore, the patent claims the use of the compound in the preparation of a drug for treating PB2-mediated diseases, specifically mentioning tumors and autoimmune diseases as examples.
In summary, the filed patent describes a compound of formula (I) and its derivatives, which have potential applications in the treatment of PB2-mediated diseases. The patent claims cover the compound itself, pharmaceutical compositions containing the compound, and the use of the compound in drug preparation for treating PB2-mediated diseases, including tumors and autoimmune diseases.
To know more about GlobalData’s detailed insights on Haisco Pharmaceutical Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
